Signaling pathways
-
BA9041 hVEGF-IN-1Summary: hVEGF-IN-1, a quinazoline derivative, specifically binds to G-rich sequences in the internal ribosome entry site A (IRES-A) and will destabilize the G-quadruplex structure. - BA9042 BucillamineSummary: Bucillamine (SA96) is an orally effective sulfhydryl donor and antioxidant.
- BA9043 VEGFR-3-IN-1Summary: VEGFR-3-IN-1 is a potent and highly selective inhibitor.
- BA9044 VEGFR2-IN-2Summary: VEGFR2-IN-2 is a potent and selective inhibitor.
- BA9045 SoziniberceptSummary: Sozinibercept (OPT302; VGX-300) is a soluble form that effectively inhibits the activity of angiogenic factors, inhibiting angiogenesis and vascular leakage.
- BA9046 VEGFR2-IN-7Summary: VEGFR2-IN-7 is an inhibitor.
- BA9047 BrolucizumabSummary: Brolucizumab (DLX1008) is a single-chain anti-antibody fragment with low picomolar affinity (=1.05 pM).
- BA9048 AcrizanibSummary: Acrizanib (LHA510) is an inhibitor.
- BA9049 Ziv-afliberceptSummary: Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor.
- BA9050 SU5214Summary: SU5214 is a potent inhibitor.